IPAA

2024 NAPE Summit Attendee Registration Surges 47% Over Prior Year

Retrieved on: 
Wednesday, November 8, 2023
Technology, Mining, Minerals, Other Energy, Nuclear, Utilities, Other Technology, Natural Resources, Oil, Gas, Coal, Alternative Energy, Energy, Bitcoin, AAPL, SEG, Renewable energy, Prospect, IPAA, Education, AAPG, Multimedia, NAPE, Cryptocurrency

As of NAPE’s “preferred rate” deadline, registration for the 2024 NAPE Summit is up a whopping 47% compared with the same time frame for the 2023 expo.

Key Points: 
  • As of NAPE’s “preferred rate” deadline, registration for the 2024 NAPE Summit is up a whopping 47% compared with the same time frame for the 2023 expo.
  • View the full release here: https://www.businesswire.com/news/home/20231108346112/en/
    Over 8,000 dealmakers explore the 2023 NAPE Summit expo floor.
  • In addition to oil and gas prospects, the expanding NAPE Hubs will focus on Renewable Energy, Bitcoin Mining and — new for 2024 — Minerals & Nonoperating.
  • Act fast — NAPE Summit priority rates end Dec. 8, 2023.

Nokia and Virgin Media O2 extend 5G RAN deal to continue improving connectivity in the UK

Retrieved on: 
Monday, June 19, 2023
Cloud, Single, Partnership, Nokia, Next Generation Mobile Networks, Radio access network, G-Cloud, IPAA, SOC, RAN, Virgin Media, MIMO, United Kingdom, Growth, United, Virgin Media O2, Mobile phone, Hábrók

This will help enable Virgin Media O2 to accelerate its 5G coverage rollout.

Key Points: 
  • This will help enable Virgin Media O2 to accelerate its 5G coverage rollout.
  • As part of the deal, Virgin Media O2 has the option to launch a pilot of Nokia’s commercial intelligent controller to demonstrate the promise of advanced 5G use cases.
  • The agreement also means that Virgin Media O2 may pilot 5G Cloud RAN in the future, enhancing the potential of existing cloud infrastructure with 5G wireless connectivity.
  • Jeanie York, Chief Technology Officer at Virgin Media O2, commented: “We continue to invest in our network upgrading and expanding our 4G and 5G networks to customers across the country.

Takeda Announces Results From Phase 4 Vedolizumab Study in Patients With Chronic Pouchitis Published in New England Journal of Medicine

Retrieved on: 
Thursday, March 30, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Inflammation, The New England Journal of Medicine, University, Week, Chronic pain, TAK, IPAA, Ulcerative colitis, NEJM, Fecal incontinence, Kennedy Institute, UC, Patient, European, Pouchitis, Treatment, University of Oxford, Pharmaceutical industry, Birth control, Takeda, Gastroenterology

Takeda ( TSE:4502/NYSE:TAK ) today confirmed that the New England Journal of Medicine (NEJM) has published positive data from the Phase 4 EARNEST study of vedolizumab for the treatment of chronic pouchitis.

Key Points: 
  • Takeda ( TSE:4502/NYSE:TAK ) today confirmed that the New England Journal of Medicine (NEJM) has published positive data from the Phase 4 EARNEST study of vedolizumab for the treatment of chronic pouchitis.
  • The NEJM article is titled “ Vedolizumab for the Treatment of Chronic Pouchitis ”.
  • A potentially curative surgical option for ulcerative colitis (UC) is total proctocolectomy, followed by creation of an ileal pouch anal anastomosis (IPAA) to aid in stool retention.
  • The publication concluded that vedolizumab was more effective than placebo for inducing remission in chronic pouchitis after IPAA for patients with UC.

Applied Molecular Transport Announces FDA Orphan Drug Designation Granted to AMT-101 for Treatment of Pouchitis

Retrieved on: 
Thursday, November 10, 2022
Quality of life, AMTI, SAN, GLOBE, Rheumatoid arthritis, Ulcerative colitis, Marketing, U.S. Securities and Exchange Commission, Pouchitis, Pain scale, Abdominal pain, FDA, Food, Nasdaq, IE, Orphan, UC, Technology, Population, CMV, Incontinence, Magazine, Securities Act of 1933, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Fecal incontinence, IBD, SEC, Chronic pain, Safety, Ulcer, Securities Exchange Act of 1934, Patient, CA, Kelly Gebo, IPAA, Inflammation, Autoimmunity, Disease, Program, AMT, Terminology, Colectomy, OR, GMP, Growth, Security (finance), Drug Quality and Security Act, Cytomegalovirus, RA, SAE, Pharmaceutical industry, Vaccine

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT) today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for AMT-101 in patients with pouchitis, an indication with significant unmet medical need and no current FDA-approved products.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT) today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for AMT-101 in patients with pouchitis, an indication with significant unmet medical need and no current FDA-approved products.
  • Rapid onset of stool frequency response was demonstrated as early as week 2 in both dosage groups and was maintained through the duration of treatment.
  • Acute pouchitis often responds to antibiotic treatment but up to 50% of pouchitis patients develop chronic pouchitis where patients often relapse on or do not respond to antibiotic therapy.
  • Active transport is an efficient mechanism that uses the cells own machinery to transport materials across the IE barrier.

Cosmo announces FDA grants orphan-drug designation of rifamycin for treatment of pouchitis

Retrieved on: 
Saturday, October 22, 2022
IPAA, Incontinence, Colon, Hospital, Endoscopy, Tenesmus, Patient, XETRA, Ansamycin, Medtronic, ODD, GI, Partnership, Orphan drug, Degenerative disease, Rectum, Malnutrition, Pouchitis, CEO, UC, Incidence, Ulcerative colitis, Fever, C43, Dehydration, FDA, Pharmaceutical industry, EU

Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (Cosmo) announces that the FDA has granted the orphan-drug designation request of rifamycin for treatment of pouchitis.

Key Points: 
  • Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (Cosmo) announces that the FDA has granted the orphan-drug designation request of rifamycin for treatment of pouchitis.
  • Cosmo has conceived and developed a novel formulation to deliver Rifamycin SV, an antibiotic belonging to the Ansamycin family, to treat pouchitis.
  • The granting of the Orphan Drug Designation (ODD) by the FDA is an essential step to streamline and accelerate the development of a much-needed treatment.
  • Alessandro Della Ch, CEO of Cosmo, said: The grant of the ODD for Rifamycin from the FDA to treat pouchitis is another major advancement of our GI pipeline of innovative products.

NAPE Announces Inaugural Class of ‘NAPE Hall of Fame’ Inductees

Retrieved on: 
Monday, October 17, 2022
Other Energy, Oil, Gas, Coal, Alternative Energy, Energy, Nuclear, IPAA, LinkedIn, American Association of Professional Landmen, Sale, AAPL, Saint Arnold Brewing Company, RPL, SEG, Organization, Â, Longevity, Education, Twitter, Independent Petroleum Association of America, Industry, American Association, Association, Society, George R. Brown Convention Center, AAPG, Fame-class ship of the line, Society of Exploration Geophysicists, NAPE, Saint Arnold, List of halls and walks of fame, Leadership, Perfume, Video game, CPL

We are thrilled to celebrate our inaugural Hall of Fame inductees and recognize their role in creating the place where deals happen, said Grant Johnson, RPL, chair of the NAPE Advisory Board.

Key Points: 
  • We are thrilled to celebrate our inaugural Hall of Fame inductees and recognize their role in creating the place where deals happen, said Grant Johnson, RPL, chair of the NAPE Advisory Board.
  • During the upcoming NAPE Classic Plus event, the NAPE Hall of Fame Class of 2023 will be officially recognized at the NAPE 30th Anniversary Kickoff Party at Saint Arnold Brewing Company in Houston on Oct. 25.
  • Inductees will also be honored at a special Hall of Fame area at NAPE Summit in February.
  • To stay connected on all things NAPE, please visit NAPEexpo.com and follow NAPE on Twitter @NAPE_EXPO, Facebook @NAPEexpo, Instagram @napeexpo and LinkedIn .

Applied Molecular Transport Announces Positive Top-line Phase 2 Results from FILLMORE Trial of Oral AMT-101 in Patients with Chronic Pouchitis

Retrieved on: 
Monday, April 25, 2022
Patient, SAE, Pain scale, AMT, Cytomegalovirus, RA, DMC, Population, U.S. Securities and Exchange Commission, Security (finance), Yale University, CA, GMP, Autoimmunity, Program, Drug Quality and Security Act, Infection, Terminology, Inflammation, Securities Exchange Act of 1934, Growth, Fecal incontinence, CMV, Company, Pouchitis, IBD, UC, SEC, Harvard University, Epidemiology, Webcast, Biostatistics, Division, Safety, IE, Magazine, Colectomy, FDA, Quality of life, Disease, Kelly Gebo, Securities Act of 1933, Abdominal pain, Western University, IPAA, Incontinence, Vaccine, Pharmaceutical industry, Medicine, Gastroenterology

SOUTH SAN FRANCISCO, Calif., April 25, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT) today announced positive top-line Phase 2 results from the FILLMORE monotherapy trial for AMT-101 in patients with chronic pouchitis, an orphan indication with significant unmet medical need and no current FDA-approved therapies. AMT-101 is an investigational, once-daily, GI-selective, oral fusion of IL-10 and AMT’s proprietary carrier molecule, which is also in development for the treatment of ulcerative colitis (UC) and rheumatoid arthritis (RA).

Key Points: 
  • The FILLMORE independent DMC recommends advancing AMT-101 to Phase 3 with the 3mg dose in chronic pouchitis, based on its review of safety and efficacy data available to date.
  • The live webcast will be accessible via the Events page of the Applied Molecular Transport website at https://ir.appliedmt.com/news-events/events .
  • FILLMORE is a Phase 2 double-blinded trial that evaluated the safety and efficacy of orally administered AMT-101 monotherapy, over 12 weeks, in patients with chronic pouchitis.
  • Acute pouchitis often responds to antibiotic treatment but up to 50% of pouchitis patients develop chronic pouchitis where patients often relapse on or do not respond to antibiotic therapy.

The European Private LTE Market Will Grow to USD$ 2,020.88 Million by 2028, at a CAGR of 12.2% - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 22, 2022
Technology, Internet, Telecommunications, CommScope, CAGR, FDD, Transport, Health, Growth, Energy, Research, Cisco Systems, Radio, TDD, Sustainable Energy Utility, Samsung, Solution, Nokia, IOT, COVID-19, LTE, Awareness, IPAA, Internet, Telecommunication, Communications satellite, Mobile phone, Health care, Mining

The report provides trends prevailing in the Europe private LTE market along with the drivers and restraints pertaining to the market growth.

Key Points: 
  • The report provides trends prevailing in the Europe private LTE market along with the drivers and restraints pertaining to the market growth.
  • Inflated demand for reliable and efficient communications network infrastructure is the major factor driving the growth of the Europe private LTE market.
  • However, issues associated with the invigorated exploitation of IoT devices hinder the growth of Europe's private LTE market.
  • The Europe private LTE market is segmented into component, type, end user, and country.